BC Extra | Apr 9, 2014
Financial News

AdvanDx secures $12 million in B-1 round

Molecular diagnostics company AdvanDx Inc. (Woburn, Mass.) raised $9 million in a $12 million series B-1 round led by new investor Merck Global Health Innovation Fund. Existing investors SLS Ventures and LD Pensions also participated....
BC Week In Review | Sep 17, 2012
Company News

AdvanDx sales and marketing update

AdvanDx will launch the QuickFISH 20 Min. Pathogen ID test in the U.S. and EU on Sept. 24 to identify pathogens, including Staphylococcus aureus and coagulase-negative staphylococci that cause bloodstream infections. The molecular diagnostic that...
Items per page:
1 - 2 of 2